CHRISTINE BURNS: Open Payments
NPI 1700902012 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$953 in 46 payments from 8 companies in 2025. Trend: 2023 $2,037 · 2024 $2,046 · 2025 $953
Food & beverage: $854Education: $99
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 7 | $180 |
| Regeneron Healthcare Solutions, Inc. | 15 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $170 |
| GlaxoSmithKline, LLC. | 6 | $157 |
| AstraZeneca Pharmaceuticals LP | 1 | $112 |
| SANOFI-AVENTIS U.S. LLC | 1 | $99 |
| BioCryst US Sales Co., LLC | 2 | $37 |
| Optinose US, Inc. | 1 | $27 |
Products named: DUPIXENT, NUCALA, HYQVIA, AIRSUPRA, ORLADEYO, CUVITRU, Xhance, TAKHZYRO.
Industry payments across NV — which companies pay providers there.
